![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Tungs’ Taichung Metroharbour Hospital |
Information provided by: | Tungs’ Taichung Metroharbour Hospital |
ClinicalTrials.gov Identifier: | NCT00431249 |
Peripheral arterial disease (PAD) is the most common manifestation of systemic atherosclerosis and accounts for significant morbidity and mortality among end-stage renal disease (ESRD) patients. However, few studies have identified the prevalence and clinical impact of PAD in this specific population.
Objectives: To perform a single-blinded parallel, controlled trial to examine the effect of cilostazol treatment on plasma VEGF levels, tissue factors , inflammatory markers (such as IL-6, hsCRP) levels, oxidative stress markers in ESRD patients with PAD Material and methods Fourty HD patients on maintenance HD for > 3months were enrolled in this prospective, single-blinded, randomized study. These patients were randomly allocated into 2 arms. After baseline assessment, patients in the treatment arm received 12 weeks of added on therapy with cilostazol 100mg/day. Blood pressure, heart rate, oxidative stress (malonyldialdehyde, protein carbonyl and ADMA), inflammatory markers (hsCRP, IL-6) and plasma, VEGF and tissue factors levels were measured before and after treatment.
Condition | Intervention | Phase |
Hemodialysis Patients Peripheral Vascular Disease |
Drug: Cilostazol |
Phase IV |
MedlinePlus related topics: | Dialysis Kidney Failure Peripheral Arterial Disease Stress Vascular Diseases |
Drug Information available for: | Cilostazol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment |
Official Title: | Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease. |
Estimated Enrollment: | 70 |
Study Start Date: | February 2007 |
Study Completion Date: | April 2008 |
![]() |
Show Detailed Description |
Ages Eligible for Study: | 30 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 960126 |
First Received: | February 2, 2007 |
Last Updated: | April 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00431249 |
Health Authority: | Taiwan: Department of Health |
|
|
|
![]() |